Current status and perspective in the diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma
10.3760/cma.j.cn112330-20230522-00179
- VernacularTitle:延胡索酸水合酶缺陷型肾细胞癌诊治的现状和展望
- Author:
Tao WANG
1
;
Xin MA
;
Qingbo HUANG
;
Xiaohui DING
;
Juan DONG
;
Tao SONG
;
Gang GUO
;
Xu ZHANG
Author Information
1. 解放军总医院泌尿外科医学部，北京 100039
- Keywords:
Carcinoma, Renal cell;
FH-deficient renal cell carcinoma;
Diagnosis;
Treatment;
Prognosis
- From:
Chinese Journal of Urology
2023;44(6):466-470
- CountryChina
- Language:Chinese
-
Abstract:
Fumarate hydratasedeficient renal cell carcinoma(FH-RCC)is s a rare and highly aggressive and metastatic form of renal cell carcinoma. Clinical diagnosis is relatively challenging, and there is a lack of recognized systemic treatment options. Therefore, in clinical practice, it is necessary to have a deeper understanding of this disease and fully integrate family history, imaging findings, and pathological manifestations for clinical identification, and genetic testing shoule be conducted when necessary. Improved patient prognosis can be achieved through the selection of appropriate curative surgery or systemic treatment strategies.
